BHCM
EW icon

Brevan Howard Capital Management’s Edwards Lifesciences EW Stock Holding History

Brevan Howard Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16M Buy
34,889
+1,773
+5% +$149K 0.02% 526
2026
Q1 		$2.65M Sell
33,116
-35,564
-52% -$2.93M 0.02% 451
2025
Q4 		$5.89M Buy
68,680
+22,408
+48% +$1.84M 0.06% 204
2025
Q3 		$3.6M Sell
46,272
-33,100
-42% -$2.59M 0.02% 328
2025
Q2 		$6.21M Buy
79,372
+73,154
+1,176% +$5.46M 0.04% 299
2025
Q1 		$451K Sell
6,218
-5,649
-48% -$404K ﹤0.01% 751
2024
Q4 		$879K Buy
11,867
+8,712
+276% +$610K 0.01% 461
2024
Q3 		$208K Sell
3,155
-27,034
-90% -$1.96M ﹤0.01% 981
2024
Q2 		$2.79M Buy
30,189
+19,870
+193% +$1.76M 0.02% 155
2024
Q1 		$986K Buy
10,319
+4,469
+76% +$375K 0.01% 275
2023
Q4 		$446K Buy
+5,850
New +$407K 0.01% 533

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Brevan Howard Capital Management's EW Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Edwards Lifesciences (EW) stake by 5.4% in Q2 2026, buying an estimated $149K and bringing the position to 34,889 shares worth $3.16M. The position accounts for 0.02% of the portfolio, ranked #526.

Brevan Howard Capital Management first reported a position in EW in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.21M in Q2 2025. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Brevan Howard Capital Management held 34,889 shares of Edwards Lifesciences worth $3.16M as of Q2 2026.
  • Brevan Howard Capital Management bought 1,773 Edwards Lifesciences shares in Q2 2026, an estimated $149K.
  • Edwards Lifesciences made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #526 holding.
  • Brevan Howard Capital Management first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 11 quarters since.
  • Brevan Howard Capital Management's Edwards Lifesciences position peaked at $6.21M in Q2 2025.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.